» Articles » PMID: 26449141

40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients

Overview
Date 2015 Oct 10
PMID 26449141
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are limited long-term, single-cohort, follow-up studies available about patients after the Fontan operation.

Objectives: This study sought to determine the long-term outcome of all patients who had a Fontan operation at the Mayo Clinic.

Methods: Records of all patients who had a modified Fontan operation between 1973 and 2012 were reviewed. A follow-up questionnaire was mailed to all patients alive at the time of the study.

Results: Overall, 10-, 20-, and 30-year survival for 1,052 patients was 74%, 61%, and 43%, respectively. Factors associated with decreased overall or late survival in multivariate analysis included pre-operative diuretic use, longer cardiopulmonary bypass time, operation prior to 1991, atrioventricular valve (AVV) replacement at the time of Fontan operation, elevated post-bypass Fontan (>20 mm Hg) or left atrial (>13 mm Hg) pressures, prolonged chest tube drainage (>21 days), post-operative ventricular arrhythmias, renal insufficiency, and development of protein-losing enteropathy (PLE). Pre-operative and intraoperative sinus rhythm were associated with improved survival. Long-term survival was similar for patients regardless of ventricular morphology. The most common reoperations were pacemaker insertion/revision in 212 patients (20%), Fontan revision/conversion in 117 patients (11%), and AVV repair/replacement in 66 patients (5%). Clinically significant late atrial or ventricular arrhythmias occurred in 468 patients (44%). Ninety-five patients (9%) developed PLE, and 5-, 10-, and 20-year survival after diagnosis of PLE was 50%, 35%, and 19%, respectively.

Conclusions: As the surgical techniques for the Fontan operation have changed over the last 40 years, survival has improved. However, development of PLE and arrhythmias and the need for reoperation during long-term follow-up pose significant management challenges.

Citing Articles

Fontan-Associated Liver Disease (FALD) in the EUROFontan Experience. An Insight into European Awareness.

Gozzi A, Vedovelli L, Bergonzoni E, Cao I, Angeli E, Zanoni R Pediatr Cardiol. 2025; .

PMID: 40080110 DOI: 10.1007/s00246-025-03781-0.


Are Arrhythmias Adequately Incorporated into Studies on Long-Term Outcomes After the Fontan Operation?.

Pexton N, Balaji S Pediatr Cardiol. 2025; .

PMID: 39984710 DOI: 10.1007/s00246-025-03789-6.


Interventions for adult congenital heart disease.

Cepas-Guillen P, Flores-Umanzor E, Horlick E, Aboulhosn J, Benson L, Freixa X Nat Rev Cardiol. 2025; .

PMID: 39833478 DOI: 10.1038/s41569-025-01118-1.


Biventricular Repair of Univentricular Heart Lowers Risk of Liver Disease Compared With the Fontan Operation.

Ghbeis M, Pane C, Beroukhim R, Feins E, Del Nido P, Sleeper L JACC Adv. 2025; 4(1):101429.

PMID: 39801815 PMC: 11720947. DOI: 10.1016/j.jacadv.2024.101429.


Long-term survival in patients with univentricular heart: A nationwide, register-based cohort study.

Ozturk A, Dellborg M, Damlin A, Giang K, Mandalenakis Z, Sorensson P Int J Cardiol Congenit Heart Dis. 2024; 15:100503.

PMID: 39713494 PMC: 11657339. DOI: 10.1016/j.ijcchd.2024.100503.